Mitochondrial dysfunction induced by beta-amyloid peptides (Aβ) has been identified as an early marker during the development of AD, mainly characterized by the brain metabolism disorder, the dysregulation of calcium homeostasis, and the rising ROS level (Guo et al., 2019). Here, APP is linked to Alzheimer disease.